贝达药业：贝福替尼在PFS数据方面的良好表现显示了临床治疗上的差异化能力

Core Viewpoint - Betta Pharmaceuticals has demonstrated the differentiated clinical efficacy of its drug, Beifuqun, with favorable progression-free survival (PFS) data and controllable safety profile, indicating potential for effective market promotion and patient benefit [1] Group 1: Clinical Research and Product Development - Clinical research results indicate that Beifuqun shows good performance in PFS data, highlighting its differentiated clinical treatment capability [1] - The overall adverse event safety profile of Beifuqun is manageable, suggesting a strong safety record [1] - The company plans to leverage the data advantages of Beifuqun to develop effective promotional strategies [1] Group 2: Commercialization and Revenue Growth - The company aims to achieve comprehensive market coverage quickly, benefiting more patients through its successful commercialization experience with already launched products [1] - The collaboration with Yifang is ongoing, with both parties communicating to resolve new developments in their commercial partnership [1] - The company has established a robust revenue growth and cash flow through a virtuous cycle of "R&D - commercialization - reinvestment," ensuring orderly advancement of its R&D pipeline [1] Group 3: Future Prospects - Recent interim data from the postoperative adjuvant clinical trial of Ensatinib has reached the study endpoint, marking a significant achievement in resource concentration and development focus [1] - This achievement is expected to have a positive impact on the company's future revenue [1]